A randomized, double-blind, placebo-controlled, parallel group 26-week dose-investigating study to explore the pharmacokinetics, pharmacodynamic effects, efficacy, safety and tolerability of RO5186582 in children with Down syndrome aged 6-11 years.

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2015 - September 30, 2016